Pan Hui, DU Hong-Wei
Department of Pediatrics, First Bethune Hospital of Jilin University, Changchun 130021, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2024 May 15;26(5):444-449. doi: 10.7499/j.issn.1008-8830.2310001.
Recombinant human growth hormone (rhGH) is an effective therapeutic drug for improving short stature. Currently, rhGH can be used for various causes of short stature, including growth hormone deficiency, and the expansion of its clinical application has raised concerns about its safety. Based on existing evidence, when rhGH is used in a standardized manner for physiological replacement therapy, its safety profile is favorable. In clinical practice, attention should be focused on short-term safety during rhGH treatment, with the combination of literature evidence and clinical experience. There is still no definitive conclusion on the long-term safety due to insufficient duration of rhGH treatment. This paper reviews the possible adverse events that may occur during rhGH treatment and their risk control measures, aiming to help clinical physicians understand the overall safety of rhGH treatment and improve its clinical standardization.
重组人生长激素（rhGH）是一种用于改善身材矮小的有效治疗药物。目前，rhGH可用于多种导致身材矮小的原因，包括生长激素缺乏症，其临床应用的扩大引发了对其安全性的担忧。基于现有证据，当rhGH以标准化方式用于生理替代治疗时，其安全性良好。在临床实践中，应结合文献证据和临床经验，关注rhGH治疗期间的短期安全性。由于rhGH治疗时间不足，关于其长期安全性尚无定论。本文综述了rhGH治疗期间可能发生的不良事件及其风险控制措施，旨在帮助临床医生了解rhGH治疗的整体安全性并提高其临床规范性。
